
Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for many disorders, including malignant and non-malignant disorders. However, a fully matched related donor is available only for 25% of patients, and, despite over 31 million of volunteer donors, about 50% patients cannot find a suitable donor in a reasonable frame-time. Therefore, strategies to optimize the use of mismatched donors are urgently needed. The use of donors HLA-partially matched (haploidentical) is becoming widely used and in 2021 we can say that, thanks to new graft manipulation strategies we have a donor for everyone.